Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells

被引:91
作者
Chiu, YY
Higaki, K
Neudeck, BL
Barnett, JL
Welage, LS
Amidon, GL
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Okayama Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Okayama 7008350, Japan
[3] Univ Michigan, Univ Hosp, Serv Pharm, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Med Ctr, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
关键词
intestinal permeability; P-glycoprotein; cyclosporin A; biopharmaceutic classification system; Caco-2 cell culture; MICROEMULSION FORMULATION; HEALTHY-SUBJECTS; PHARMACOKINETICS; TRANSPORT; DRUG; BIOAVAILABILITY; PROPRANOLOL; ABSORPTION; SANDIMMUN; BEHAVIOR;
D O I
10.1023/A:1023481418576
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this work was to determine the jejunal permeability of cyclosporin A (CsA) in humans and whether formulation variables modulate the effects of P-glycoprotein (P-gp) on the permeability of CsA in Caco-2 cells. Methods. A solution containing CsA, phenylalanine, propranolol, polyethyleneglycol ( PEG) 400, and PEG 4000 was perfused through a 10-cm jejunal segment in 12 subjects. Caco-2 transport studies were performed using previously reported methodology. Results. The mean P-eff (+/-SD) of CsA in humans was 1.65 (0.53). The mean permeabilities for phenylalanine, propranolol, and PEG 400 were 4.54 (2.39), 2.90 (1.28), and 0.83 (0.51) x 10(-4) cm/s, respectively. The presence of surfactants significantly decreased the permeabilities of CsA in both directions in Caco-2 cells. Conclusions. The results suggest that the effects of surfactants via micellar solubilization and inhibition of P-gp efflux on CsA transport in Caco-2 cells are significant. CsA can rightly be classified as a low solubility-high permeability Class II BCS drug and its highly variable absorption from Sandimmune(R) oral formulations is the result of poor dissolution characteristics.
引用
收藏
页码:749 / 756
页数:8
相关论文
共 31 条
[1]   A SENSITIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF PROPRANOLOL IN SERUM [J].
ALANGARY, AA ;
ELSAYED, YM ;
ALMESHAL, MA ;
ALDARDIRI, MM ;
MAHROUS, GM .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1991, 16 (02) :93-101
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]  
AWNI WM, 1998, J CHROMATOGR, V425, P233
[4]   Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers [J].
Batrakova, EV ;
Han, HY ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 1998, 15 (06) :850-855
[5]   DIFFERENTIAL INTERACTION OF HUMAN RENAL P-GLYCOPROTEIN WITH VARIOUS METABOLITES AND ANALOGS OF CYCLOSPORINE-A [J].
CHARUK, JHM ;
WONG, PY ;
REITHMEIER, RAF .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1995, 269 (01) :F31-F39
[6]   CYCLOSPORINE METABOLISM IN TRANSPLANT PATIENTS [J].
CHRISTIANS, U ;
SEWING, KF .
PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) :291-345
[7]  
Chu XY, 2001, J PHARMACOL EXP THER, V299, P575
[8]   THE ABSORPTION SITE OF CYCLOSPORINE IN THE HUMAN GASTROINTESTINAL-TRACT [J].
DREWE, J ;
BEGLINGER, C ;
KISSEL, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) :39-43
[9]   Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A [J].
Gao, ZG ;
Choi, HG ;
Shin, HJ ;
Park, KM ;
Lim, SJ ;
Hwang, KJ ;
Kim, CK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 161 (01) :75-86
[10]   PHARMACOKINETICS OF ORAL CYCLOSPORINE-A (SANDIMMUN) IN HEALTHY-SUBJECTS [J].
GREVEL, J ;
NUESCH, E ;
ABISCH, E ;
KUTZ, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :211-216